Optical Coherence Tomography-Based Grading of Diabetic Macular Edema Is Associated with Systemic Inflammatory Indices and Imaging Biomarkers
- PMID: 38211574
- DOI: 10.1159/000535199
Optical Coherence Tomography-Based Grading of Diabetic Macular Edema Is Associated with Systemic Inflammatory Indices and Imaging Biomarkers
Abstract
Introduction: Objectives of the study were to investigate the correlation between optical coherence tomography (OCT)-based grading of diabetic macular edema (DME) and systemic inflammatory indices, imaging biomarkers, and early anti-vascular endothelial growth factor (VEGF) treatment response.
Methods: A total of 111 eyes from 111 patients with DME treated with intravitreous anti-VEGF therapy for 3 consecutive months every month were enrolled in this retrospective study. According to a protocol termed "TCED," DME was divided into early, advanced, severe, and atrophic stages. The best-corrected visual acuity (BCVA), subretinal fluid (SRF), and the number of hyperreflective foci (HRF) in the whole retinal layers were analyzed at baseline and 3 months after the first injection. Peripheral blood inflammatory indices were calculated, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet (PLT)-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and C-reactive protein (CRP). Statistical analysis was performed to compare the visual and anatomical results and evaluate HRF and SRF in different stages of DME before and after treatment.
Results: There were significant differences in systemic inflammatory indices among the four groups, including NLR, PLR, MLR, SII, and CRP (all p < 0.05). The CRP, NLR, PLR, MLR, and SII were significantly higher in the atrophic stage compared to the advanced stage (all p < 0.05). Conversely, the CRP, NLR, PLR, MLR, and SII were significantly lower in the advanced stage compared to the early stage (all p < 0.05). Except for the atrophic stage, BCVA and central retinal thickness (CRT) were significantly improved after treatment in early, advanced and severe stages (all p < 0.05), especially in the severe stage. The decline in the proportion of SRF and HRF ≥20 was the most significant in the advanced stage after anti-VEGF treatment (p < 0.001, p = 0.016), but not in the early and severe stages (all p > 0.05).
Conclusion: Systemic inflammatory indices and the decline in the proportion of SRF and HRF ≥20 were closely associated with different stages of DME based on "TCED." Meanwhile, the "TCED" grading system can predict visual and anatomical prognosis of DME after anti-VEGF treatment, which may be a biomarker for identifying risk stratification and management of DME.
Keywords: Biomarker; Diabetic macular edema; Grade; Inflammation; Optical coherence tomography; Stage.
© 2024 The Author(s). Published by S. Karger AG, Basel.
Similar articles
-
Hyperreflective Foci in Diabetic Macular Edema with Subretinal Fluid: Association with Visual Outcomes after Anti-VEGF Treatment.Ophthalmic Res. 2023;66(1):39-47. doi: 10.1159/000525412. Epub 2022 Jun 13. Ophthalmic Res. 2023. PMID: 35697006
-
Predictive Role of Complete Blood Count-Derived Inflammation Indices and Optical Coherence Tomography Biomarkers for Early Response to Intravitreal Anti-VEGF in Diabetic Macular Edema.Biomedicines. 2025 May 27;13(6):1308. doi: 10.3390/biomedicines13061308. Biomedicines. 2025. PMID: 40564027 Free PMC article.
-
Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections.Medicina (Kaunas). 2023 Mar 21;59(3):629. doi: 10.3390/medicina59030629. Medicina (Kaunas). 2023. PMID: 36984630 Free PMC article.
-
Anti-VEGF therapy for the long-term management of diabetic macular edema: a treat-to-target strategy based on macular morphology.Graefes Arch Clin Exp Ophthalmol. 2024 Dec;262(12):3749-3759. doi: 10.1007/s00417-024-06558-y. Epub 2024 Jul 12. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38995350 Free PMC article. Review.
-
Ultrastructural imaging biomarkers in diabetic macular edema: A major review.Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S7-S23. doi: 10.4103/IJO.IJO_878_24. Epub 2024 Dec 24. Indian J Ophthalmol. 2025. PMID: 39723865 Free PMC article. Review.
Cited by
-
Wide-Field Optical Coherence Tomography in Patients with Diabetic Macular Edema.J Clin Med. 2024 Jul 20;13(14):4242. doi: 10.3390/jcm13144242. J Clin Med. 2024. PMID: 39064281 Free PMC article.
-
Exploring leukocyte differential count ratio profiles as inflammatory biomarkers in diabetic retinopathy: a systematic review and meta-analysis.BMC Ophthalmol. 2025 May 1;25(1):265. doi: 10.1186/s12886-025-04075-y. BMC Ophthalmol. 2025. PMID: 40312699 Free PMC article.
-
Systemic inflammatory markers and neurovascular changes in the retina and choroid of diabetic patients without retinopathy: insights from wide-field SS-OCTA.Front Med (Lausanne). 2025 Jun 4;12:1566047. doi: 10.3389/fmed.2025.1566047. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40534690 Free PMC article.
-
Systemic inflammatory response index as a predictive biomarker for Irvine-Gass syndrome.Int Ophthalmol. 2025 Jul 24;45(1):315. doi: 10.1007/s10792-025-03680-6. Int Ophthalmol. 2025. PMID: 40705180
-
The Predictors of Early Treatment Effectiveness of Intravitreal Bevacizumab Application in Patients with Diabetic Macular Edema.Diagnostics (Basel). 2024 May 10;14(10):992. doi: 10.3390/diagnostics14100992. Diagnostics (Basel). 2024. PMID: 38786290 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous